Odyssey Group International/Prevacus, Inc. Reports Brain Bio-Distribution Findings of PRV-002
Odyssey Group International, Inc. (OTCQB:ODYY) and Prevacus Inc. announced positive pre-clinical results for PRV-002, a nasal drug aimed at treating concussions. The studies indicated that PRV-002 demonstrated rapid brain absorption, with enhanced bioavailability when formulated as nanoparticles. After nasal administration, approximately 40% more of the drug was detected in brain tissues after 8 hours compared to its native form. Odyssey is set to finalize its acquisition of PRV-002 by the end of February, contingent on shareholder approval.
- PRV-002 shows rapid absorption in the brain, enhancing treatment options for concussions.
- About 40% more of PRV-002 observed in brain cortices when administered as nanoparticles.
- Transaction to acquire PRV-002 expected to close soon, indicating progress in drug development.
- No FDA-approved treatment currently exists for concussion, indicating market uncertainty.
- Completion of the acquisition is contingent on shareholder approval, posing potential delays.
Pre-clinical data for PRV-002, a nasally delivered drug in development for treating concussion, highlight rapid brain bioavailability
IRVINE, CA / ACCESSWIRE / February 17, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, and Prevacus Inc., are pleased to report the results of pre-clinical studies related to brain biodistribution of PRV-002 (Prevasol), a novel compound in development for the treatment of concussion.
In this study, PRV-002, a neurosteroid, was formulated in its native form and as a nanoparticle. Pre-clinical animal studies of PRV-002 have shown rapid absorption in the brain with biodistribution across the entire brain when administered nasally.
"We are pleased to see such a significant level of the compound reach the brain over the 8-hour period of nasal administration. These data confirm our hypothesis that the administration of nasal nanoparticles improves brain bioavailability. PRV-002 was most concentrated in the frontal lobe, which makes perfect sense given its direct connection with the olfactory nerves. Nasal application is ideal for quick, on-the-field administration and conditions of acute brain inflammation where immediate treatment is critical." said Dr. Jake VanLandingham, Chief Executive Officer of Prevacus.
In this study, conducted by Inotiv for Prevacus, both forms of PRV-002 were nasally administered to subjects three times: one initial dose and two subsequent doses given in 4-hour intervals. Brain tissue was analyzed at 8-hours post-initial nasal application. When formulated as a nanoparticle, approximately
Michael Redmond, CEO of Odyssey added, "concussion is a serious health issue in sports, the military and in elderly populations which currently has no FDA approved drug treatment. These animal data support PRV-002's brain bioavailability following brain trauma. We are eager to close our transaction and contribute to the drug development program."
Odyssey previously entered into a definitive agreement with Prevacus to acquire the Active Pharmaceutical Ingredient PRV-002 (Prevasol) to treat traumatic brain injury on January 11, 2021. The definitive agreement has been signed, and the transaction is expected to close by the end of February 2021. The transaction is conditional on Prevacus shareholder approval and other customary closing conditions.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
SOURCE: Odyssey Group International, Inc
View source version on accesswire.com:
https://www.accesswire.com/630171/Odyssey-Group-InternationalPrevacus-Inc-Reports-Brain-Bio-Distribution-Findings-of-PRV-002
FAQ
What is the latest on ODYY's PRV-002 for concussion treatment?
When is ODYY expected to finalize the acquisition of PRV-002?
What are the benefits of PRV-002 as reported by ODYY?
What does ODYY's acquisition of PRV-002 mean for investors?
